Clinical trial
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia…
NCT00003693 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003693 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia |
| Official title | Phase I Study of Dolastatin-10 in Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Dolastatin 10 |
| Enrollment | 30 |
| Start date | Dec 18, 1998 |
| Primary completion | Oct 30, 2001 |
| Completion | Oct 30, 2001 |
| First posted | Mar 23, 2004 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: